Citations (86)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Motoki Ochi, Kohnosuke Kinoshita, Jun-ichi Yamaguchi & Hiromi Endo. (2022) Bottom-up physiologically based pharmacokinetic modelling for predicting the human pharmacokinetic profiles of the ester prodrug MGS0274 and its active metabolite MGS0008, a metabotropic glutamate 2/3 receptor agonist. Xenobiotica 52:2, pages 119-128.
Read now
Read now
Jia Chen, Dongyang Liu, Xin Zheng, Qian Zhao, Ji Jiang & Pei Hu. (2015) Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug–drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling. Expert Opinion on Drug Metabolism & Toxicology 11:6, pages 857-868.
Read now
Read now
Yoshiya Yamamura, Noriyuki Koyama & Ken Umehara. (2015) Comprehensive kinetic analysis and influence of reaction components for chlorzoxazone 6-hydroxylation in human liver microsomes with CYP antibodies. Xenobiotica 45:4, pages 353-360.
Read now
Read now
G. I. Somers, M. K. Bayliss & J. B. Houston. (2007) The metabolism of the 5HT3 antagonists, ondansetron, alosetron and GR87442 II: Investigation into the in vitro methods used to predict the in vivo hepatic clearance of ondansetron, alosetron and GR87442 in the rat, dog and human. Xenobiotica 37:8, pages 855-869.
Read now
Read now
D Springer, R. F Staack, L. D Paul, T Kraemer & H. H Maurer. (2005) Identification of cytochrome P450 enzymes involved in the metabolism of 3′,4′-methylenedioxy-α-pyrrolidinopropiophenone (MDPPP), a designer drug, in human liver microsomes. Xenobiotica 35:3, pages 227-237.
Read now
Read now
R. F. Staack, D. S. Theobald, L. D. Paul, D. Springer, T. Kraemer & H. H. Maurer. (2004) In vivo metabolism of the new designer drug 1-(4-methoxyphenyl)piperazine (MeOPP) in rat and identification of the human cytochrome P450 enzymes responsible for the major metabolic step. Xenobiotica 34:2, pages 179-192.
Read now
Read now
Shufeng Zhou, Yihuai Gao, Wenqi Jiang, Min Huang, Anlong Xu & James W. Paxton. (2003) Interactions of Herbs with Cytochrome P450. Drug Metabolism Reviews 35:1, pages 35-98.
Read now
Read now
Slobodan Rendic. (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metabolism Reviews 34:1-2, pages 83-448.
Read now
Read now
David F.V. Lewis & Maurice Dickins. (2001) Quantitative Structure-Activity Relationships (QSARs) Within Series of Inhibitors for Mammalian Cytochromes P450 (CYPs). Journal of Enzyme Inhibition 16:4, pages 321-330.
Read now
Read now
A. B. Renwick, G. Lavignette, P. D. Worboys, B. Williams, D. Surry, D. F. V. Lewis, R. J. Price, B. G. Lake & D. C. Evans. (2001) Evaluation of 7-benzyloxy-4-trifluoromethylcoumarin, some other 7-hydroxy-4-trifluoromethylcoumarin derivatives and 7-benzyloxyquinoline as fluorescent substrates for rat hepatic cytochrome P450 enzymes. Xenobiotica 31:12, pages 861-878.
Read now
Read now
R. J. Weaver. (2001) Assessment of drug-drug interactions: concepts and approaches. Xenobiotica 31:8-9, pages 499-538.
Read now
Read now
M. A. M. WENKER, S. KEŽIĆ, A. C. MONSTER & F. A. DE WOLFF. (2001) Metabolism of styrene in the human liver in vitro: interindividual variation and enantioselectivity. Xenobiotica 31:2, pages 61-72.
Read now
Read now
A. B. Renwick, D. Surry, R. J. Price, B. G. Lake & D. C. Evans. (2000) Metabolism of 7-benzyloxy-4-trifluoromethylcoumarin by human hepatic cytochrome P450 isoforms. Xenobiotica 30:10, pages 955-969.
Read now
Read now
Articles from other publishers (73)
Blanche C Ip, Samantha J Madnick, Sophia Zheng, Tessa C A van Tongeren, Susan J Hall, Hui Li, Suzanne Martin, Sandrine Spriggs, Paul Carmichael, Wei Chen, David Ames, Lori A Breitweiser, Heather E Pence, Andrew J Bowling, Kamin J Johnson, Richard Cubberley, Jeffrey R Morgan & Kim Boekelheide. (2024) Development of a human liver microphysiological coculture system for higher throughput chemical safety assessment. Toxicological Sciences.
Crossref
Crossref
Hlengwa N., Masilela C.Mtambo T. R., Sithole S.Naidoo S., Machaba K. E.Shabalala S. C., Ntamo Y.Dludla P. V. & Milase R. N.. (2023) In Vitro Hepatic Models to Assess Herb–Drug Interactions: Approaches and Challenges. Pharmaceuticals 16:3, pages 409.
Crossref
Crossref
David M. Stresser & Arian Emami-Riedmaier. 2021. Enzyme Kinetics in Drug Metabolism. Enzyme Kinetics in Drug Metabolism
653
664
.
Olivia Goethe, Abigail Heuer, Xiaoshen Ma, Zhixun Wang & Seth B. Herzon. (2019) Antibacterial properties and clinical potential of pleuromutilins. Natural Product Reports 36:1, pages 220-247.
Crossref
Crossref
Jin Lu, Lili Wan, Yuan Zhong, Qi Yu, Yonglong Han, Pengguo Chen, Beiyun Wang, Wei Li, Ya Miao & Cheng Guo. (2015) Stereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with Alzheimer's disease. Journal of Pharmacological Sciences 129:3, pages 188-195.
Crossref
Crossref
Markus R. Meyer, Sandra Mauer, Golo M. J. Meyer, Julia Dinger, Birgit Klein, Folker Westphal & Hans H. Maurer. (2013)
The
in vivo
and
in vitro
metabolism and the detectability in urine of 3’,4’‐methylenedioxy‐alpha‐pyrrolidinobutyrophenone (MDPBP), a new pyrrolidinophenone‐type designer drug, studied by GC‐MS and LC‐MS
n
. Drug Testing and Analysis 6:7-8, pages 746-756.
Crossref
Crossref
Markus R. Meyer, Anja Robert & Hans H. Maurer. (2014) Toxicokinetics of novel psychoactive substances: Characterization of N-acetyltransferase (NAT) isoenzymes involved in the phase II metabolism of 2C designer drugs. Toxicology Letters 227:2, pages 124-128.
Crossref
Crossref
Xiaofeng Li, Tom Suhar, Lateca Glass & Ganesh Rajaraman. 2001. Current Protocols in Pharmacology. Current Protocols in Pharmacology
9.18.1
9.18.10
.
Golo M.J. Meyer, Markus R. Meyer, Carina S.D. Wink, Josef Zapp & Hans H. Maurer. (2013) Studies on the in vivo contribution of human cytochrome P450s to the hepatic metabolism of glaucine, a new drug of abuse. Biochemical Pharmacology 86:10, pages 1497-1506.
Crossref
Crossref
Shannon Dallas, Carlo Sensenhauser, Souvik Chattopadhyay & Jose Silva. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
24
.
Lushan Yu, Yan Jiang, Lu Wang, Rong Sheng, Yongzhou Hu & Su Zeng. (2013) Metabolism of BYZX in Human Liver Microsomes and Cytosol: Identification of the Metabolites and Metabolic Pathways of BYZX. PLoS ONE 8:3, pages e59882.
Crossref
Crossref
Xiaohai Li, Xinyi Song, Theodore M. Kamenecka & Michael D. Cameron. (2012) Discovery of a Highly Selective CYP3A4 Inhibitor Suitable for Reaction Phenotyping Studies and Differentiation of CYP3A4 and CYP3A5. Drug Metabolism and Disposition 40:9, pages 1803-1809.
Crossref
Crossref
Carol M. Porter & Brian G. Miller. (2012) Cooperativity in monomeric enzymes with single ligand-binding sites. Bioorganic Chemistry 43, pages 44-50.
Crossref
Crossref
Chun Li & Nataraj Kalyanaraman. 2012. ADME‐Enabling Technologies in Drug Design and Development. ADME‐Enabling Technologies in Drug Design and Development
189
212
.
Bella Pajares, Esperanza Torres, José Manuel Trigo, María Isabel Sáez, Nuria Ribelles, Begoña Jiménez & Emilio Alba. (2012) Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations. Clinical and Translational Oncology 14:2, pages 94-101.
Crossref
Crossref
Markus R. Meyer, Christian Vollmar, Andrea E. Schwaninger, Ehud (Udi) Wolf & Hans H. Maurer. (2012) New cathinone‐derived designer drugs 3‐bromomethcathinone and 3‐fluoromethcathinone: studies on their metabolism in rat urine and human liver microsomes using GC–MS and LC–high‐resolution MS and their detectability in urine. Journal of Mass Spectrometry 47:2, pages 253-262.
Crossref
Crossref
Jakob Jornil, Klaus Gjervig Jensen, Frank Larsen & Kristian Linnet. (2010) Identification of Cytochrome P450 Isoforms Involved in the Metabolism of Paroxetine and Estimation of Their Importance for Human Paroxetine Metabolism Using a Population-Based Simulator. Drug Metabolism and Disposition 38:3, pages 376-385.
Crossref
Crossref
X W Teng, D J Cutler & N M Davies. (2003) Kinetics of metabolism and degradation of mometasone furoate in rat biological fluids and tissues. Journal of Pharmacy and Pharmacology 55:5, pages 617-630.
Crossref
Crossref
David J. Greenblatt & Lisa L. von Moltke. 2010. Enzyme- and Transporter-Based Drug-Drug Interactions. Enzyme- and Transporter-Based Drug-Drug Interactions
625
649
.
Takaki Toda, Erik Eliasson, Birgitta Ask, Nobuo Inotsume & Anders Rane. (2009) Roles of Different CYP Enzymes in the Formation of Specific Fluvastatin Metabolites by Human Liver Microsomes. Basic & Clinical Pharmacology & Toxicology 105:5, pages 327-332.
Crossref
Crossref
Markus R. Meyer, Frank T. Peters & Hans H. Maurer. (2009) Investigations on the human hepatic cytochrome P450 isozymes involved in the metabolism of 3,4-methylenedioxy-amphetamine (MDA) and benzodioxolyl-butanamine (BDB) enantiomers. Toxicology Letters 190:1, pages 54-60.
Crossref
Crossref
Markus R. Meyer, Frank T. Peters & Hans H. Maurer. (2009) The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxyethylamphetamine and Its Single Enantiomers. Drug Metabolism and Disposition 37:6, pages 1152-1156.
Crossref
Crossref
Markus R. Meyer, Frank T. Peters & Hans H. Maurer. (2009) Stereoselective differences in the cytochrome P450-dependent dealkylation and demethylenation of N-methyl-benzodioxolyl-butanamine (MBDB, Eden) enantiomers. Biochemical Pharmacology 77:11, pages 1725-1734.
Crossref
Crossref
Rowan A. Stringer, Claire Strain-Damerell, Paul Nicklin & J. Brian Houston. (2009) Evaluation of Recombinant Cytochrome P450 Enzymes as an in Vitro System for Metabolic Clearance Predictions. Drug Metabolism and Disposition 37:5, pages 1025-1034.
Crossref
Crossref
Christoph Sauer, Frank T. Peters, Andrea E. Schwaninger, Markus R. Meyer & Hans H. Maurer. (2009) Investigations on the cytochrome P450 (CYP) isoenzymes involved in the metabolism of the designer drugs N-(1-phenyl cyclohexyl)-2-ethoxyethanamine and N-(1-phenylcyclohexyl)-2-methoxyethanamine. Biochemical Pharmacology 77:3, pages 444-450.
Crossref
Crossref
Kenneth Bachmann. 2009. Pharmacology. Pharmacology
131
173
.
Markus R. Meyer, Frank T. Peters & Hans H. Maurer. (2008) The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxy-Methamphetamine and Its Enantiomers. Drug Metabolism and Disposition 36:11, pages 2345-2354.
Crossref
Crossref
Christoph Sauer, Frank T. Peters, Andrea E. Schwaninger, Markus R. Meyer & Hans H. Maurer. (2008)
Identification of Cytochrome P450 Enzymes Involved in the Metabolism of the Designer Drugs
N
-(1-Phenylcyclohexyl)-3-ethoxypropanamine and
N
-(1-Phenylcyclohexyl)-3-methoxypropanamine
. Chemical Research in Toxicology 21:10, pages 1949-1955.
Crossref
Crossref
Frank T. Peters, Markus R. Meyer, Denis S. Theobald & Hans H. Maurer. (2008) Identification of Cytochrome P450 Enzymes Involved in the Metabolism of the New Designer Drug 4′-Methyl-α-pyrrolidinobutyrophenone. Drug Metabolism and Disposition 36:1, pages 163-168.
Crossref
Crossref
Denis S. Theobald & Hans H. Maurer. (2007) Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series). Biochemical Pharmacology 73:2, pages 287-297.
Crossref
Crossref
Verawan Uchaipichat, Peter I. Mackenzie, David J. Elliot & John O. Miners. (2006) SELECTIVITY OF SUBSTRATE (TRIFLUOPERAZINE) AND INHIBITOR (AMITRIPTYLINE, ANDROSTERONE, CANRENOIC ACID, HECOGENIN, PHENYLBUTAZONE, QUINIDINE, QUININE, AND SULFINPYRAZONE) “PROBES” FOR HUMAN UDP-GLUCURONOSYLTRANSFERASES. Drug Metabolism and Disposition 34:3, pages 449-456.
Crossref
Crossref
Sandra Coecke, Hans Ahr, Bas J. Blaauboer, Susanne Bremer, Silvia Casati, Josè Castell, Robert Combes, Raffaella Corvi, Charles L. Crespi, Michael L. Cunningham, Greetje Elaut, Brighitta Eletti, Andreas Freidig, Alessandra Gennari, Jean-François Ghersi-Egea, Andre Guillouzo, Thomas Hartung, Peter Hoet, Magnus Ingelman-Sundberg, Sharon Munn, Walter Janssens, Bernhard Ladstetter, David Leahy, Anthony Long, Annarita Meneguz, Mario Monshouwer, Siegfried Morath, Fred Nagelkerke, Olavi Pelkonen, Jessica Ponti, Pilar Prieto, Lysianne Richert, Enrico Sabbioni, Beatrice Schaack, Winfried Steiling, Emanuela Testai, Joan-Albert Vericat & Andrew Worth. (2019)
Metabolism: A Bottleneck in
In Vitro
Toxicological Test Development
. Alternatives to Laboratory Animals 34:1, pages 49-84.
Crossref
Crossref
C. F. Peet, T. Enos, R. Nave, K. Zech & M. Hall. (2005) Identification of enzymes involved in Phase I metabolism of ciclesonide by human liver microsomes. European Journal of Drug Metabolism and Pharmacokinetics 30:4, pages 275-286.
Crossref
Crossref
Shuko Tachibana, Yuko Fujimaki, Hiroyuki Yokoyama, Osamu Okazaki & Ken-ichi Sudo. (2005)
IN VITRO METABOLISM OF THE CALMODULIN ANTAGONIST DY-9760e (3-[2-[4-(3-CHLORO-2-METHYLPHENYL)-1-PIPERAZINYL]ETHYL]-5,6-DIMETHOXY-1-(4-IMIDAZOLYLMETHYL)-1
H
-INDAZOLE DIHYDROCHLORIDE 3.5 HYDRATE) BY HUMAN LIVER MICROSOMES: INVOLVEMENT OF CYTOCHROMES P450 IN ATYPICAL KINETICS AND POTENTIAL DRUG INTERACTIONS
. Drug Metabolism and Disposition 33:11, pages 1628-1636.
Crossref
Crossref
Gregor Zlokarnik, Peter D.J. Grootenhuis & John B. Watson. (2005) High throughput P450 inhibition screens in early drug discovery. Drug Discovery Today 10:21, pages 1443-1450.
Crossref
Crossref
Toshiro NIWAToshifumi SHIRAGAAkira TAKAGI. (2005) Drug-Drug Interaction of Antifungal Drugs抗真菌剤の薬物相互作用—薬物代謝酵素に及ぼす影響—. YAKUGAKU ZASSHI 125:10, pages 795-805.
Crossref
Crossref
Jonathan N. Bauman, Theunis C. Goosen, Meera Tugnait, Vincent Peterkin, Susan I. Hurst, Lee C. Menning, Mark Milad, Michael H. Court & J. Andrew Williams. (2005) UDP-GLUCURONOSYLTRANSFERASE 2B7 IS THE MAJOR ENZYME RESPONSIBLE FOR GEMCABENE GLUCURONIDATION IN HUMAN LIVER MICROSOMES. Drug Metabolism and Disposition 33:9, pages 1349-1354.
Crossref
Crossref
Yueh-Ching Chou, Yune-Fang Ueng, Chia-Yu Chou & Jung-Hsiung Tien. (2005) Dimemorfan N-demethylation by mouse liver microsomal cytochrome P450 enzymes. Life Sciences 77:7, pages 735-745.
Crossref
Crossref
Theresa Mariero Klees, Pamela Sheffels, Ola Dale & Evan D. Kharasch. (2005) METABOLISM OF ALFENTANIL BY CYTOCHROME P4503A (CYP3A) ENZYMES. Drug Metabolism and Disposition 33:3, pages 303-311.
Crossref
Crossref
Monette M Cotreau, Lisa L von Moltke & David J Greenblatt. (2005) The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates. Clinical Pharmacokinetics 44:1, pages 33-60.
Crossref
Crossref
Toshiro NiwaSachiko Inoue-YamamotoToshifumi ShiragaAkira Takagi. (2005) Effect of Antifungal Drugs on Cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 Activities in Human Liver Microsomes. Biological and Pharmaceutical Bulletin 28:9, pages 1813-1816.
Crossref
Crossref
Toshiro NiwaToshifumi ShiragaAkira Takagi. (2005) Effect of Antifungal Drugs on Cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 Activities in Human Liver Microsomes. Biological and Pharmaceutical Bulletin 28:9, pages 1805-1808.
Crossref
Crossref
Thomas Kraemer, Thomas Pflugmann, Michael Bossmann, Nicole M Kneller, Frank T Peters, Liane D Paul, Dietmar Springer, Roland F Staack & Hans H Maurer. (2004) Fenproporex N-dealkylation to amphetamine—enantioselective in vitro studies in human liver microsomes as well as enantioselective in vivo studies in Wistar and Dark Agouti rats. Biochemical Pharmacology 68:5, pages 947-957.
Crossref
Crossref
Robert D. Combes. (2019)
The Case for Taking Account of Metabolism when Testing for Potential Endocrine Disruptors
In Vitro
. Alternatives to Laboratory Animals 32:2, pages 121-135.
Crossref
Crossref
Li Di, Edward H. Kerns, Ning Gao, Susan Q. Li, Youping Huang, Jim L. Bourassa & Donna M. Huryn. (2004) Experimental Design on Single-Time-Point High-Throughput Microsomal Stability Assay. Journal of Pharmaceutical Sciences 93:6, pages 1537-1544.
Crossref
Crossref
Roland F. Staack, Denis S. Theobald, Liane D. Paul, Dietmar Springer, Thomas Kraemer & Hans H. Maurer. (2004)
IDENTIFICATION OF HUMAN CYTOCHROME P450 2D6 AS MAJOR ENZYME INVOLVED IN THE
O
-DEMETHYLATION OF THE DESIGNER DRUG
P
-METHOXYMETHAMPHETAMINE
. Drug Metabolism and Disposition 32:4, pages 379-381.
Crossref
Crossref
Steve Hood. 2004. A Handbook of Bioanalysis and Drug Metabolism. A Handbook of Bioanalysis and Drug Metabolism.
Robert S. Foti & Michael B. Fisher. (2004) IMPACT OF INCUBATION CONDITIONS ON BUFURALOL HUMAN CLEARANCE PREDICTIONS: ENZYME LABILITY AND NONSPECIFIC BINDING. Drug Metabolism and Disposition 32:3, pages 295-304.
Crossref
Crossref
John O. MinersPaul A. SmithMichael J. SorichRoss A. McKinnonPeter I. Mackenzie. (2004) Predicting Human Drug Glucuronidation Parameters: Application of In Vitro and In Silico Modeling Approaches. Annual Review of Pharmacology and Toxicology 44:1, pages 1-25.
Crossref
Crossref
Keith W. Ward, Gary J. Stelman, Jayme A. Morgan, Kelli S. Zeigler, Leonard M. Azzarano, Jonathan R. Kehler, Jeanelle E. McSurdy-Freed, Joel W. Proksch & Brian R. Smith. (2004) DEVELOPMENT OF AN IN VIVO PRECLINICAL SCREEN MODEL TO ESTIMATE ABSORPTION AND FIRST-PASS HEPATIC EXTRACTION OF XENOBIOTICS. II. USE OF KETOCONAZOLE TO IDENTIFY P-GLYCOPROTEIN/CYP3A-LIMITED BIOAVAILABILITY IN THE MONKEY. Drug Metabolism and Disposition 32:2, pages 172-177.
Crossref
Crossref
David M. Stresser, Marc I. Broudy, Thuy Ho, Catherine E. Cargill, Andrew P. Blanchard, Raman Sharma, Andre A. Dandeneau, Joseph J. Goodwin, Stephanie D. Turner, John C. L. Erve, Christopher J. Patten, Shangara S. Dehal & Charles L. Crespi. (2004) HIGHLY SELECTIVE INHIBITION OF HUMAN CYP3A IN VITRO BY AZAMULIN AND EVIDENCE THAT INHIBITION IS IRREVERSIBLE. Drug Metabolism and Disposition 32:1, pages 105-112.
Crossref
Crossref
Roland F Staack, Liane D Paul, Dietmar Springer, Thomas Kraemer & Hans H Maurer. (2004) Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). Biochemical Pharmacology 67:2, pages 235-244.
Crossref
Crossref
Brian G. Lake, Roger J. Price, David G. Walters, John C. Phillips, Philip J. Young & Timothy B. Adams. (2003) Studies on the metabolism of the thiofurans furfuryl mercaptan and 2-methyl-3-furanthiol in rat liver. Food and Chemical Toxicology 41:12, pages 1761-1770.
Crossref
Crossref
Kyoung-Ah Kim, Min-Jung Kim, Ji-Young Park, Ji-Hong Shon, Young-Ran Yoon, Sang-Seop Lee, Kwang-Hyeon Liu, Jin-Ho Chun, Myung-Ho Hyun & Jae-Gook Shin. (2003) STEREOSELECTIVE METABOLISM OF LANSOPRAZOLE BY HUMAN LIVER CYTOCHROME P450 ENZYMES. Drug Metabolism and Disposition 31:10, pages 1227-1234.
Crossref
Crossref
Dietmar Springer, Liane D. Paul, Roland F. Staack, Thomas Kraemer & Hans H. Maurer. (2003) IDENTIFICATION OF CYTOCHROME P450 ENZYMES INVOLVED IN THE METABOLISM OF 4′-METHYL-α-PYRROLIDINOPROPIOPHENONE, A NOVEL SCHEDULED DESIGNER DRUG, IN HUMAN LIVER MICROSOMES. Drug Metabolism and Disposition 31:8, pages 979-982.
Crossref
Crossref
Denis Projean, Bruno Baune, Robert Farinotti, Jean-Pierre Flinois, Philippe Beaune, Anne-Marie Taburet & Julie Ducharme. (2003)
IN VITRO METABOLISM OF CHLOROQUINE: IDENTIFICATION OF CYP2C8, CYP3A4, AND CYP2D6 AS THE MAIN ISOFORMS CATALYZING
N
-DESETHYLCHLOROQUINE FORMATION
. Drug Metabolism and Disposition 31:6, pages 748-754.
Crossref
Crossref
M. Teresa Donato & Jos?? V. Castell. (2003) Strategies and Molecular Probes to Investigate the Role of Cytochrome P450 in Drug Metabolism. Clinical Pharmacokinetics 42:2, pages 153-178.
Crossref
Crossref
. (2002) Chapter 7: Biokinetics. Alternatives to Laboratory Animals 30:1_suppl, pages 55-70.
Crossref
Crossref
Toshiro Niwa, Yumi Maekawa, Megumi Fujimoto, Kae KishimotoYoshiyasu YabusakiFumihide Ishibashi & Masanao Katagiri. (2002) Inhibition of Human Hepatic Cytochrome P450s and Steroidogenic CYP17 by Nonylphenol.. Biological and Pharmaceutical Bulletin 25:2, pages 235-238.
Crossref
Crossref
Karthik Venkatakrishnan, Lisa L. von Moltke & David J. Greenblatt. (2013) Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro Models. The Journal of Clinical Pharmacology 41:11, pages 1149-1179.
Crossref
Crossref
Annabelle Le Gal, Yvonne Dréano, Pier-Giovanni Gervasi & François Berthou. (2001) Human cytochrome P450 2A6 is the major enzyme involved in the metabolism of three alkoxyethers used as oxyfuels. Toxicology Letters 124:1-3, pages 47-58.
Crossref
Crossref
Peter Hlavica & David F. V. Lewis. (2008) Allosteric phenomena in cytochrome P450‐catalyzed monooxygenations. European Journal of Biochemistry 268:18, pages 4817-4832.
Crossref
Crossref
David Lewis. 2001. Guide to Cytochromes P450. Guide to Cytochromes P450
164
210
.
A.David Rodrigues & Jiunn H Lin. (2001) Screening of drug candidates for their drug–drug interaction potential. Current Opinion in Chemical Biology 5:4, pages 396-401.
Crossref
Crossref
A. David Rodrigues, Gregory A. Winchell & Michael R. Dobrinska. (2013) Use of In Vitro Drug Metabolism Data to Evaluate Metabolic Drug‐Drug Interactions in Man: The Need for Quantitative Databases. The Journal of Clinical Pharmacology 41:4, pages 368-373.
Crossref
Crossref
Genevieve Ubeaud, Claus-Ditter Schiller, Fabrice Hurbin, Daniel Jaeck & Philippe Coassolo. (2001) Comparison of the stability of some major cytochrome P450 and conjugation reactions in rat, dog and human hepatocyte monolayers. European Journal of Drug Metabolism and Pharmacokinetics 26:1-2, pages 37-45.
Crossref
Crossref
Thomas Thum & Jürgen Borlak. (2009) Cytochrome P450 mono‐oxygenase gene expression and protein activity in cultures of adult cardiomyocytes of the rat. British Journal of Pharmacology 130:8, pages 1745-1752.
Crossref
Crossref
Bhama Parimoo & Paul E. Thomas. (2000) Epitope Mapping of Rat Cytochrome P450 2B1 Using Glutathione S-Transferase-2B1 Fusion Constructs. Archives of Biochemistry and Biophysics 380:1, pages 117-125.
Crossref
Crossref
Ronald E. White. (2000) High-Throughput Screening in Drug Metabolism and Pharmacokinetic Support of Drug Discovery. Annual Review of Pharmacology and Toxicology 40:1, pages 133-157.
Crossref
Crossref
Ray Bakhtiar & Randall W. Nelson. (2000) Electrospray ionization and matrix-assisted laser desorption ionization mass spectrometry. Biochemical Pharmacology 59:8, pages 891-905.
Crossref
Crossref
Thomas Thum & Jürgen Borlak. (2000) Gene expression in distinct regions of the heart. The Lancet 355:9208, pages 979-983.
Crossref
Crossref
Geoffrey T. Tucker. (2000) Advances in Understanding Drug Metabolism and Its Contribution to Variability in Patient Response. Therapeutic Drug Monitoring 22:1, pages 110-113.
Crossref
Crossref
Pavel Souček. (1999) Expression of Cytochrome P450 2A6 in Escherichia coli: Purification, Spectral and Catalytic Characterization, and Preparation of Polyclonal Antibodies. Archives of Biochemistry and Biophysics 370:2, pages 190-200.
Crossref
Crossref